1-2 of 2
David Fitchett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial

Subodh Verma, C. David Mazer, Deepak L. Bhatt, Satish R. Raj, Andrew T. Yan, Atul Verma, Ele Ferrannini, Gudrun Simons, Jisoo Lee, Bernard Zinman, Jyothis T. George, David Fitchett
Journal: Diabetes Care
Diabetes Care 2019;42(3):e42–e44
DOI: https://doi.org/10.2337/dc18-1959
Published: 23 January 2019
View article titled, Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
Open the PDF for Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial in another window
Journal Articles

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin
Journal: Diabetes Care
Diabetes Care 2018;41(2):356–363
DOI: https://doi.org/10.2337/dc17-1096
Published: 04 December 2017
View article titled, How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Open the PDF for How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial in another window
Includes: Supplementary data